Open an account

Fibrobiologics

FBLG · NASDAQ

$0.9199−$0.0199 (−2.12%)TodayMarket closed ·
Prev close $0.9398

FBLG analyst rating

HoldConsensus of 3 analysts over the last 12 months. 33% rate it a buy.
  • Strong buy0
  • Buy1
  • Hold2
  • Underperform0
  • Sell0

12-month price target · 3 analysts

Average $6.12 (+565.3% upside)

Low
$6.06
Now
$0.9199
High
$6.30

Upgrades and downgrades

The latest rating actions, newest first

FBLG analyst upgrades, downgrades and rating actions
FirmDateActionRating
HC Wainwright & Co.Aug 4, 2026MaintainsBuy
Maxim GroupMay 4, 2026DowngradeBuy → Hold
HC Wainwright & Co.Apr 16, 2026MaintainsBuy
D. Boral CapitalMar 26, 2026DowngradeBuy → Hold
D. Boral CapitalMar 12, 2026MaintainsBuy
HC Wainwright & Co.Feb 26, 2026MaintainsBuy
D. Boral CapitalFeb 25, 2026MaintainsBuy
D. Boral CapitalJan 6, 2026MaintainsBuy
HC Wainwright & Co.Jan 2, 2026MaintainsBuy
D. Boral CapitalNov 20, 2025MaintainsBuy

The case for and against

Updated Sep 15, 2026

Bull case

FibroBiologics is expected to see a boost in institutional appeal and potential capital raises due to the announced 1-for-20 reverse stock split and completion of a $3 million public offering, which will help fund operations as they continue to progress their fibroblast-based therapy programs. The company's valuation is also supported by the anticipation of successful clinical validation for their DFU treatment during the first half of 2026. However, risks include failure to achieve peak commercial revenue and secure sufficient capital resources, as well as ongoing clinical and regulatory obstacles. With these factors in mind, analysts rate the stock as a Buy and have adjusted their price target to $8 per share, based on expected earnings multiple and discounted cash flow projections.

Bear case

FibroBiologics is facing potential challenges with its upcoming proof-of-concept interim clinical results for its CYWC628 fibroblast therapy in diabetic foot ulcer (DFU) patients, which are expected in the first half of 2026. While the company has made recent moves to comply with Nasdaq's listing requirements and raise capital through a public offering, the outlook for the broader therapeutic fibroblast pipeline is uncertain due to the lack of clinical validation and the need for conservative market penetration estimates. Additionally, the company may face challenges with competing therapies and poor treatment outcomes in the DFU market.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.